Stockhub

Kazia Therapeutics Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 September 2022

  • curprev 11:1411:14, 23 September 2022 95.149.241.133 talk 662 bytes +662 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed..."
Retrieved from "https://stockhub.co/research/Kazia_Therapeutics_Limited"